Last update:
Weight management news
New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells
Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2). Studies show that the new drug, CBL-514, ...
4 hours ago
0
4
Low-calorie diet and exercise put early-onset type 2 diabetes in remission for 54% of participants
New research presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and appearing in The Lancet Regional Health Americas journal shows that in people ...
13 hours ago
0
131
A molecular switch syncs fat burning to the body clock, our diet and the temperature around us
Brown fat burns fuel to make heat, and this activity is controlled by the body clock: It drops during sleep and rises before waking. But a cold morning or a skipped meal makes demands the clock never planned for. How the ...
Oct 1, 2026
0
15
GLP-1 prescriptions for new mothers have increased sharply
More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.
Oct 1, 2026
0
7
New triple agonist drug produces substantial weight loss in diabetic patients
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and appearing in The Lancet shows that treatment with the new triple agonist ...
Oct 1, 2026
0
72
Clinical trial provides preliminary evidence of blood-pressure effect from feijoa
The world's first clinical trial of feijoa has provided preliminary evidence that the fruit reduces blood pressure during weight loss. The unexpected finding was incidental to studying feijoa's potential for preventing type ...
Oct 1, 2026
0
46
Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections ...
Sep 30, 2026
0
75
Focusing on the 'obesity paradox' to improve cancer treatment success
In research published in the journal Nature, McGill University researchers looked at the relationship between diet, the gut microbiome and patient response to immune checkpoint blockade. To their surprise, certain diets often ...
Sep 30, 2026
0
20
Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that ...
Sep 30, 2026
0
116
Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased ...
Sep 30, 2026
0
13
GLP-1s appear safe for treating diabetes in pregnancy, but evidence gaps remain
New research to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Obstetrics, Gynaecology & Women's Health shows ...
Sep 30, 2026
0
17
Higher GLP-1 costs lead to lower adherence
Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor's instructions. But a new study from the University of Georgia suggests patients aren't taking the weight loss medication ...
Sep 30, 2026
0
4
New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
New data from a phase 2b study being presented at the 2026 annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), show that, for people living with obesity and type ...
Sep 30, 2026
0
10
Women are and will be the predominant users of GLP-1 users, but research gaps remain critical
The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health ...
Sep 30, 2026
0
5
Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct. 2 examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children ...
Sep 30, 2026
0
3
Major trial examines sugar-free sweetened soft drinks
Researchers at the University of Liverpool have conducted the longest and most comprehensive randomized controlled trial of non-nutritive sweetened (NNS) soft drinks.
Sep 29, 2026
0
1111
Cutting calories sheds weight initially, but body changes can drive regain
In the last few years, there's been a lot of interest in calorie-restricted diets for weight loss.
Sep 29, 2026
0
9
Q&A: What are ultra-processed foods?
Nearly every day, there's a headline about ultra-processed foods, which have been linked to harmful health effects despite lacking a universally accepted definition. These foods are the subject of numerous proposed regulations, ...
Sep 29, 2026
0
4
EU launches first Screening Week to help detect heart and diabetes risks earlier
At a press conference at the EASD Annual Meeting in Milan, organized by the European Diabetes Forum (EUDF), three leading European cardiometabolic scientific associations—the European Society of Cardiology (ESC), the European ...
Sep 29, 2026
0
3
How much do Americans spend on GLP-1 medications? Medical students measure drug affordability
The number of people using GLP-1 treatments like Ozempic and Wegovy for weight loss or chronic conditions has increased rapidly, with more than 1 in 10 U.S. adults currently taking such medications. A new study led by medical ...
Sep 28, 2026
0
11
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer
New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry ...
Sep 28, 2026
0
19
Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) ...
Sep 27, 2026
0
24
Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 ...
Sep 26, 2026
0
179
The higher your body fat percentage, the less accurate your smartwatch is at measuring calories burned
Smartwatches have become an increasingly popular way for people to monitor their health and fitness. About 100 million—nearly 4 in 10—U.S. adults own a smartwatch. Worldwide, market research estimates approximately 560 million ...
Sep 26, 2026
0
33
Newfound brain circuit coordinates eating and energy burning when temperatures drop
When the body's temperature falls, it adapts by burning more energy to generate heat and triggering appetite to replace the fuel used to stay warm. While scientists have known about those responses for decades, precisely ...
Sep 25, 2026
0
63
